Jaguar health reports second quarter 2023 financial results

Net revenue increased 36% in q2 2023 versus q1 2023 top line results expected late october 2023 for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the eu and middle east/north africa regions, with results expected before the end of 2023 and in 2024 reminder: jaguar to host investor webcast monday, august 14th at 8:30 a.m. eastern regarding q2 2023 financials and company updates; click here to register for webcast san francisco, ca / accesswire / august 14, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported consolidated second-quarter 2023 financial results and provided company updates.
JAGX Ratings Summary
JAGX Quant Ranking